These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 29774034)

  • 61. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
    Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S
    Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.
    Santoni M; Berardi R; Amantini C; Burattini L; Santini D; Santoni G; Cascinu S
    Int J Cancer; 2014 Jun; 134(12):2772-7. PubMed ID: 24114790
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A.
    Kadambi A; Mouta Carreira C; Yun CO; Padera TP; Dolmans DE; Carmeliet P; Fukumura D; Jain RK
    Cancer Res; 2001 Mar; 61(6):2404-8. PubMed ID: 11289105
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [VEGF and its receptors as therapeutic target in cancer therapy].
    Gisterek I; Kornafel J
    Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors.
    Verheul HM; Pinedo HM
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S80-4. PubMed ID: 11970755
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC).
    Li C; Liu B; Dai Z; Tao Y
    Cancer Biol Ther; 2011 Nov; 12(10):872-80. PubMed ID: 21989163
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Increased Regulatory T Cells and Decreased Myeloid-Derived Suppressor Cells Induced by High CCL17 Levels May Account for Normal Incidence of Cancers among Patients with Atopic Dermatitis.
    Morimura S; Sugaya M; Oka T; Suga H; Miyagaki T; Tsunemi Y; Asano Y; Sato S
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670758
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
    Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
    Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
    Gabrilovich DI; Ishida T; Nadaf S; Ohm JE; Carbone DP
    Clin Cancer Res; 1999 Oct; 5(10):2963-70. PubMed ID: 10537366
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.
    Kandalaft LE; Motz GT; Busch J; Coukos G
    Curr Top Microbiol Immunol; 2011; 344():129-48. PubMed ID: 20680802
    [TBL] [Abstract][Full Text] [Related]  

  • 74. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
    Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.
    Geindreau M; Ghiringhelli F; Bruchard M
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34064508
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
    Homsi J; Daud AI
    Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation.
    Nakamura T; Ushigome H
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103447
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
    Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
    BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
    Padró T; Bieker R; Ruiz S; Steins M; Retzlaff S; Bürger H; Büchner T; Kessler T; Herrera F; Kienast J; Müller-Tidow C; Serve H; Berdel WE; Mesters RM
    Leukemia; 2002 Jul; 16(7):1302-10. PubMed ID: 12094254
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.